Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

17.68 -0.02 (-0.11%)
Streaming Delayed Price Updated: 12:55 PM EDT, May 25, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 865,244
Open 17.71
Bid (Size) 17.67 (1)
Ask (Size) 17.68 (6)
Prev. Close 17.70
Today's Range 17.53 - 17.92
52wk Range 15.50 - 24.69
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on
Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning! 
Via InvestorPlace
This Biotech Looks Good With Increased M&A activity
Fierce Biotech backs this up: “Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for... 
Via Talk Markets

Performance

YTD
-7.82%
-7.82%
1 Month
-22.59%
-22.59%
3 Month
-9.80%
-9.80%
6 Month
+1.61%
+1.61%
1 Year
-25.34%
-25.34%

More News

Read More
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Exelixis: Q1 Earnings Insights
Via Benzinga
Earnings Scheduled For February 17, 2022
Via Benzinga
Exelixis Announces First Quarter 2022 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
Via Benzinga
Exelixis To Webcast Fireside Chats as Part of Investor Conferences in May
From Exelixis, Inc.
Via Business Wire
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Via Benzinga
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
Via Benzinga
Exelixis to Release First Quarter 2022 Financial Results on Tuesday, May 10, 2022
From Exelixis, Inc.
Via Business Wire
7 Top-Rated Biotech Stocks to Buy for Q2
Via InvestorPlace
Exelixis Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
From Exelixis, Inc.
Via Business Wire
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
From Exelixis, Inc.
Via Business Wire
Friday Markets News
Via Talk Markets
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
Via Benzinga
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Exelixis, Inc.
Via Business Wire
Flood Helping Ukraine
Via Talk Markets
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
Via Benzinga
Exelixis Will Not Pursue Untreated Liver Cancer Indication For Cabometyx Combo Therapy
Via Benzinga
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer
From Exelixis, Inc.
Via Business Wire
Futures Flat As Traders Brace For Op-Ex Volatility, More Ukraine Headlines
Via Talk Markets
Exelixis: Q4 Earnings Insights
Via Benzinga
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From Exelixis, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.